Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations-Reference-Cited by-同舟云学术

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

Published:2022-09 Issue:9 Volume:28 Page:1263-1271
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Tabarsi Payam,Anjidani Nassim,Shahpari Ramin,Mardani Masoud,Sabzvari Araz,Yazdani Babak,Roshanzamir Khashayar,Bayatani Behnam,Taheri Ali,Petrovsky Nikolai,Li Lei,Barati Saghar

Funder

National Institutes of Health

National Institute of Allergy and Infectious Diseases

CinnaGen

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference26 articles.

1. Recombinant vaccines and the development of new vaccine strategies;Nascimento;Braz J Med Biol Res,2012

2. Immunological considerations for COVID-19 vaccine strategies;Jeyanathan;Nat Rev Immunol,2020

3. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial;Richmond;Lancet,2021